Valuation: Eli Lilly and Company

Market Cap 1,106B 984B 912B 826B 1,553B 104,735B 1,579B 10,944B 4,299B 54,810B 4,147B 4,061B 174,851B P/E 2026 *
35.7x
P/E 2027 * 27.5x
Enterprise Value 1,132B 1,008B 934B 846B 1,591B 107,264B 1,617B 11,208B 4,403B 56,133B 4,247B 4,159B 179,072B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 10.9x
Free-Float
99.84%
Yield 2026 *
0.55%
Yield 2027 * 0.62%
1 day+4.04%
1 week+10.04%
Current month+10.94%
1 month+10.20%
3 months+11.92%
6 months+39.54%
Current year+19.45%
1 week 1,174.24
Extreme 1174.24
1,311.75
1 month 1,131.21
Extreme 1131.21
1,311.75
Current year 850.51
Extreme 850.51
1,311.75
1 year 793.82
Extreme 793.82
1,311.75
3 years 547.61
Extreme 547.61
1,311.75
5 years 231.87
Extreme 231.87
1,311.75
10 years 64.18
Extreme 64.18
1,311.75
Manager TitleAgeSince
Chief Executive Officer 58 2016-12-31
Director of Finance/CFO 49 2024-09-08
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 66 2004-12-31
Director/Board Member 70 2009-03-31
Director/Board Member 54 2011-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Free

Director

11 0.0000%
9/21/26 Free

Director

14 0.0000%
9/21/26 Free

Director

9 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+3.49%+10.04%+58.68%+119.56% 1,106B
+2.19%+4.32%+33.88%+69.52% 612B
+2.26%+5.37%+24.57%+97.69% 500B
+2.58%+8.31%+37.43%+63.51% 367B
+3.25%+4.45%+71.80%+44.44% 354B
+1.85%+5.45%+21.38%+49.26% 286B
+1.76%+4.92%+0.48%+20.31% 256B
+3.29%+6.32%+44.71%+57.43% 230B
+2.25%+5.81%+27.13%+101.17% 190B
+1.83%+1.87%-23.77%-61.82% 170B
Average +2.58%+1.92%+29.63%+56.11% 407.05B
Weighted average by Cap. +2.89%+2.21%+38.00%+74.62%

Financials

2026 *2027 *
Net sales 88.58B 78.85B 73.07B 66.22B 124B 8,392B 127B 877B 344B 4,391B 332B 325B 14,009B 102B 90.85B 84.2B 76.3B 143B 9,669B 146B 1,010B 397B 5,060B 383B 375B 16,142B
Net income 30.89B 27.49B 25.48B 23.09B 43.39B 2,926B 44.12B 306B 120B 1,531B 116B 113B 4,885B 40.44B 35.99B 33.36B 30.23B 56.81B 3,831B 57.76B 400B 157B 2,005B 152B 149B 6,395B
Net Debt 26.69B 23.76B 22.02B 19.95B 37.5B 2,529B 38.13B 264B 104B 1,323B 100B 98.05B 4,221B 3.27B 2.91B 2.69B 2.44B 4.59B 309B 4.66B 32.32B 12.7B 162B 12.25B 12B 516B
Projected Income Statement - Annual - Eli Lilly and Company
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
26-10-20 $1,283.66 +3.49% 2,959,648
26-10-19 $1,240.34 -1.33% 1,960,268
26-10-16 $1,257.03 +0.43% 2,413,950
26-10-15 $1,251.61 +3.55% 3,755,241
26-10-14 $1,208.74 +3.62% 3,167,443
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Eli Lilly and Company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,240.34USD
Average target price
1,331.32USD
Spread / Average Target
+7.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eli Lilly and Company